← All trials
NCT00000466
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1987
- Primary completion
- —
- Completion date
- Oct 1, 2000
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- Wake Forest UniversityOfficial
- National Institute on Aging (NIA)Collaborator
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.